Better Chikungunya virus diagnosis via Recombinant Antigens

Chikungunya virus (CHIKV) continues to be a public health challenge across Asia, Africa and Latin America. Yet, despite its widespread impact, reliable, sensitive and scalable diagnostics for Chikungunya remain limited, especially in early infection stages where viral load is low and symptom overlap with dengue or Zika makes clinical diagnosis difficult.

At Denovo Biolabs, we are helping diagnostic manufacturers and R&D teams close this gap with high-purity, recombinant antigens for Chikungunya designed, expressed and QC-validated right here in India.

Why does Chikungunya need BETTER diagnostic tools? ?

Chikungunya virus is a single-stranded RNA virus transmitted by Aedes mosquitoes.
While often self-limiting, it can cause long-term joint pain, fatigue, and in some cases, neurological complications.

The real challenge?

It’s early symptoms mimic dengue, Zika, and even COVID-19.
PCR testing has limited field adoption in low-resource settings.
Commercial ELISA kits are often unreliable due to inconsistent antigen quality.

This is where high-quality recombinant antigens come in enabling sensitive, specific, and scalable immunoassays.

Recombinant Antigens vs. Native Antigens:

Feature	Native Antigens	Recombinant Antigens
Source	Derived from infected cell cultures	Expressed from cloned genes
Safety	Requires BSL-2 or BSL-3 handling	Safe and non-infectious
Consistency	Prone to variability	Lot-to-lot reproducibility
Scale	Limited yields	Easily scalable
Customizability	Fixed composition	Domain/tag modifications possible

For ELISA, LFA, and other immunoassay formats, recombinant antigens offer a safer, cleaner, and more reliable solution.

What makes a GOOD Recombinant CHIKV Antigen? ?

At Denovo, our Chikungunya antigen development focuses on the following:

1. Targeting Immunodominant Proteins

We offer E1 and E2 envelope glycoproteins, which are key immunogenic regions responsible for antibody recognition in CHIKV patients.
These are widely studied for IgM/IgG serology kits.

2. High Expression and Purity

Expressed in E. coli or mammalian systems, our proteins are purified via affinity and size-exclusion chromatography.
Final purity: >95% (SDS-PAGE & HPLC verified).

3. Lot-to-Lot Consistency

Each batch undergoes QC validation for identity, concentration, and binding activity.
We provide CoA and protein data sheets for every production lot.

4. Assay-Ready Formats

Available in lyophilized or liquid formats, buffer-optimized for direct coating onto ELISA plates or conjugation to LFA particles.

Use Cases for our Recombinant CHIKV Antigens ?

Lateral Flow Assays (LFA):
Early screening in clinics and field settings
ELISA Kits:
Quantitative or qualitative IgM/IgG detection
Multiplex Assays:
Combined panels for DENV/Zika/CHIKV
R&D Applications:
Antibody screening, epitope mapping, and vaccine studies

Why choose Denovo Biolabs?

As part of our Make-in-India biotech initiative, Denovo Biolabs brings together R&D rigor and manufacturing capability to help India and the global South become self-reliant in critical diagnostic reagents.

✅ In-house protein design, expression and purification
✅ Batch tracking with full QC reports
✅ Bulk manufacturing for kit integration
✅ Fast lead times, local tech support
✅ Custom antigen modifications available

Also explore our:

Dengue NS1 & Envelope Protein Products
LFA-Validated Antibody Pairs for Rapid Tests
Super Sensitive TMB Substrates for ELISA Enhancement

Ready to build the BEST Chikungunya Diagnostics?

If you are developing a new LFA or optimizing an ELISA platform, our team can support your assay development, validation, and scale-up needs.